Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR: Sequential Adavosertib and Olaparib in Advanced Solid Tumors
NCT04197713Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2020
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adavosertib in solid tumor, sponsored by National Cancer Institute. Primary endpoints: Dose Limiting Toxicity at 28 days and Incidence and Causality of Treatment-Related Adverse Events. Started Jun 2020; status: active, not recruiting.
02
Drugs
adavosertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04197713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04197713.